Medical Marijuana State Programs: Comprehensive Guide to Access and Regulations

Executive Summary

Medical marijuana state programs represent the primary legal pathway through which patients access cannabis for therapeutic purposes in the United States, with 38 states, four territories, and the District of Columbia operating such systems as of May 2026. These programs emerged from state-level initiatives beginning in 1996 with California's Proposition 215, creating a patchwork of regulations that exist in tension with federal prohibition under the Controlled Substances Act. Each state program establishes its own qualifying conditions, possession limits, registry requirements, and dispensary frameworks, resulting in dramatically different patient experiences across state lines. The recent announcement that a Republican state senator plans to draft medical marijuana legislation signals continued bipartisan expansion of these programs, even as federal rescheduling efforts under the Drug Enforcement Administration's ongoing review process may fundamentally reshape the legal landscape. Medical cannabis programs now serve over 7 million registered patients nationwide, generating approximately $12 billion in annual sales and supporting thousands of licensed dispensaries, cultivation facilities, and ancillary businesses.

Why Medical Marijuana State Programs Matter

State medical cannabis programs directly impact millions of patients seeking alternatives to opioids and conventional pharmaceuticals, while generating billions in tax revenue and creating regulatory frameworks that influence federal policy debates. The stakeholder universe spans multiple dimensions. Approximately 7.3 million registered patients rely on state programs for legal access to cannabis treatments for conditions ranging from chronic pain and PTSD to epilepsy and cancer-related symptoms. These patients face varying costs, with monthly medical cannabis expenses averaging $300-600 depending on state tax structures and product availability. State governments collected over $3.8 billion in medical cannabis tax revenue in 2025, funding education, healthcare infrastructure, and regulatory oversight. The economic footprint extends to approximately 428,000 jobs across cultivation, processing, retail, testing, and compliance sectors within medical-only and dual-license states. Healthcare providers navigate complex decisions about recommending cannabis while the substance remains Schedule I under federal law, creating liability concerns and limiting research access. The American Medical Association and American Academy of Pediatrics have called for rescheduling to enable proper clinical trials, yet physicians in medical states wrote approximately 2.1 million cannabis recommendations in 2025. Multi-state operators and regional dispensaries operate under state-specific licensing regimes that prohibit interstate commerce, forcing vertical integration and creating capital inefficiencies. Medical-only markets like Mississippi and West Virginia represent growth opportunities for operators seeking first-mover advantages before potential adult-use expansion.

Background and History: From Proposition 215 to 38-State Patchwork

The modern medical marijuana movement began with California's 1996 ballot initiative and evolved through decades of state-level experimentation, federal enforcement conflicts, and gradual mainstream acceptance.

The California Breakthrough (1996)

On November 5, 1996, California voters approved Proposition 215, the Compassionate Use Act, by a 56-44 margin. The initiative allowed patients with a physician's recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, chronic pain, and any other illness for which marijuana provides relief. The law created no state licensing system for distribution, leading to a gray market of buyers' clubs and cooperatives that operated in legal ambiguity. Dennis Peron, a San Francisco activist who cared for his partner dying of AIDS, led the campaign after witnessing cannabis alleviate wasting syndrome and nausea. The initiative drew support from physicians, nurses, and patients frustrated by federal restrictions on a substance they observed providing genuine therapeutic benefit.

Early Adopter States (1998-2004)

Alaska, Oregon, and Washington followed in 1998 with voter-approved initiatives establishing medical cannabis programs with more defined structures. Maine joined via ballot measure in 1999. These early programs typically required state-issued identification cards, specified qualifying conditions, and set possession limits around 2-6 ounces of usable cannabis. Hawaii became the first state to enact medical marijuana through legislative action rather than ballot initiative in 2000, signaling that elected officials would embrace reform even without direct voter mandates. Nevada, Colorado, and Montana followed between 2000-2004, bringing the total to nine medical states by the end of President George W. Bush's first term.

Federal Conflict and the Raich Decision (2005)

The U.S. Supreme Court ruled 6-3 in Gonzales v. Raich on June 6, 2005, that the federal government could prosecute medical cannabis patients under the Commerce Clause even in states with legal programs. Angel Raich, a California patient using cannabis for a brain tumor and chronic pain, challenged DEA authority to criminalize her home cultivation. Justice John Paul Stevens wrote for the majority that homegrown cannabis substantially affected interstate markets, bringing it within federal regulatory power under Wickard v. Filburn precedent. The decision clarified that state medical marijuana laws did not provide immunity from federal prosecution, though it did not invalidate state programs themselves. The ruling prompted Congress to pass annual appropriations riders beginning in 2014 (the Rohrabacher-Farr Amendment, later Rohrabacher-Blumenauer) prohibiting the Department of Justice from using funds to interfere with state medical cannabis programs.

The Dispensary Model Emerges (2009-2012)

The Obama Administration's October 2009 Ogden Memo directed federal prosecutors not to prioritize medical marijuana patients and caregivers in clear compliance with state law, though large-scale commercial operations remained subject to enforcement. This policy shift enabled Colorado, California, and other states to develop robust dispensary systems. Colorado's 2010 regulations under HB 10-1284 created the first comprehensive seed-to-sale tracking system and vertical integration requirements, establishing a regulatory template that influenced later programs. The state required dispensaries to grow at least 70% of their inventory, mandated security protocols, and implemented mandatory testing for potency and contaminants. New Jersey enacted the Compassionate Use Medical Marijuana Act in 2010 under Governor Jon Corzine, creating one of the nation's most restrictive programs with a limited list of qualifying conditions and initially just six dispensaries statewide. The program illustrated the wide variance in state approaches, with some embracing broad access and others maintaining tight controls.

The Cole Memo Era (2013-2018)

Deputy Attorney General James Cole issued guidance on August 29, 2013, establishing eight federal enforcement priorities for marijuana cases: preventing distribution to minors, preventing revenue to criminal enterprises, preventing diversion to non-legal states, preventing state-authorized activity from covering trafficking, preventing violence, preventing drugged driving, preventing cultivation on public lands, and preventing possession on federal property. States with robust regulatory systems that addressed these priorities would face minimal federal interference. This framework enabled rapid program expansion. Illinois, New York, Maryland, Minnesota, and Pennsylvania launched medical programs between 2013-2016. By early 2017, 29 states plus Washington D.C. had operational medical cannabis programs.

The Sessions Reversal and State Defiance (2018)

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, returning discretion to individual U.S. Attorneys to prosecute marijuana cases according to federal law. The move generated bipartisan congressional opposition and did not result in widespread federal enforcement actions, as most U.S. Attorneys declined to prioritize state-compliant operations. Oklahoma voters approved State Question 788 in June 2018 by a 57-43 margin, creating one of the nation's most permissive medical programs with minimal qualifying condition restrictions and allowing physicians broad discretion in recommendations. The conservative state's embrace of medical cannabis demonstrated the issue's political evolution beyond traditional partisan divides.

Recent Expansion and Maturation (2019-2026)

Mississippi voters approved Initiative 65 in November 2020 with 74% support, though the state Supreme Court invalidated the measure on procedural grounds in May 2021. The legislature subsequently passed the Mississippi Medical Cannabis Act in February 2022, with the first dispensary sales beginning in November 2022. Alabama enacted the Darren Wesley 'Ato' Hall Compassion Act in May 2021, establishing a medical program that began patient registration in 2023. The law honored a former Auburn football player who advocated for medical access before his death. As of May 2026, 38 states operate medical marijuana programs, with recent expansion continuing in traditionally conservative states. The announcement that a Republican state senator plans to draft medical marijuana legislation reflects ongoing momentum, though the specific state was not disclosed in initial reporting.

Key Players in Medical Marijuana Programs

State medical cannabis programs involve complex interactions among regulatory agencies, licensed operators, patient advocacy organizations, medical associations, and federal enforcement bodies.

State Regulatory Agencies

Each state designates a lead agency to oversee medical cannabis programs. California's Department of Cannabis Control consolidated previously fragmented oversight in 2021. Pennsylvania's Department of Health administers the Medical Marijuana Program, while Michigan's Cannabis Regulatory Agency handles both medical and adult-use oversight. These agencies issue licenses, conduct inspections, maintain patient registries, and enforce compliance with state law. Regulatory approaches vary dramatically. New Mexico's Cannabis Control Division emphasizes social equity and rural access, while Louisiana's program operates through a limited number of licensed pharmacies. Agency staffing ranges from fewer than 10 employees in small medical-only states to over 200 in states with mature dual markets.

Multi-State Operators

Vertically integrated companies operate across multiple state medical programs despite federal prohibition on interstate commerce. Trulieve dominates Florida's medical market with over 180 dispensaries serving approximately 900,000 registered patients. Curaleaf operates in 18 states, while Green Thumb Industries, Cresco Labs, and Verano Holdings maintain significant medical market presence. These operators face unique challenges including 280E tax treatment under the Internal Revenue Code, which disallows standard business deductions for entities trafficking in Schedule I substances, effective federal tax rates exceeding 70% in some cases. Capital markets remain constrained, with U.S. operators trading on Canadian exchanges or over-the-counter markets rather than major U.S. exchanges.

Patient Advocacy Organizations

Americans for Safe Access, founded in 2002, advocates for medical cannabis patients' rights and has supported litigation challenging federal restrictions. The Epilepsy Foundation endorsed rescheduling cannabis in 2018 after observing CBD's efficacy for treatment-resistant seizures. NORML's Legal Committee provides resources for patients navigating state programs. State-specific groups like the Pennsylvania Medical Cannabis Society and Florida's Cannabis Action Network work on local policy issues including expanding qualifying conditions, reducing costs, and protecting patient employment rights.

Medical and Research Institutions

The American Academy of Neurology issued guidance in 2014 acknowledging evidence for cannabis in treating certain neurological conditions while calling for more research. The National Academies of Sciences, Engineering, and Medicine published a comprehensive 2017 review finding conclusive evidence that cannabis treats chronic pain and chemotherapy-induced nausea, with moderate evidence for sleep disorders and multiple sclerosis spasticity. Johns Hopkins University, the University of California San Diego, and the University of Colorado conduct cannabis research within federal constraints. The DEA's limitation of research-grade cannabis to a single federally licensed facility at the University of Mississippi restricted study quality until 2021, when the agency approved additional cultivation licenses for research purposes.

Federal Enforcement and Policy Bodies

The Drug Enforcement Administration maintains cannabis as Schedule I under 21 U.S.C. § 812, though the agency initiated a review of cannabis scheduling following President Biden's October 2022 directive. The Department of Health and Human Services recommended rescheduling to Schedule III in August 2023, and the DEA published a Notice of Proposed Rulemaking in May 2024 with a comment period extending into 2025. The Food and Drug Administration approved Epidiolex, a CBD-based medication for epilepsy, in 2018, and Marinol and Cesamet, synthetic THC medications, decades earlier. These approvals demonstrate the agency's position that specific cannabis-derived compounds can meet safety and efficacy standards while whole-plant cannabis remains unapproved.

Legal and Regulatory Framework

Medical marijuana programs operate within a complex legal structure where state authorization conflicts with federal prohibition, creating ongoing tension under principles of federalism and the Supremacy Clause. The Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I substance alongside heroin and LSD, defined as having high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. This classification makes cultivation, distribution, and possession federal crimes punishable by imprisonment and fines. State medical marijuana laws do not legalize cannabis under federal law but rather decline to impose state-level criminal penalties. The Tenth Amendment reserves to states police powers not delegated to the federal government, allowing states to set their own criminal codes. However, the Supremacy Clause in Article VI establishes that federal law preempts conflicting state law. The practical resolution emerged through federal prosecutorial discretion. The Rohrabacher-Blumenauer Amendment, renewed annually in appropriations bills since 2014, prohibits the Department of Justice from spending funds to prevent states from implementing medical cannabis laws. Courts have interpreted this to bar federal prosecution of individuals in clear compliance with state medical programs, as established in United States v. McIntosh (9th Cir. 2016). State programs typically include several common elements. Qualifying medical conditions are specified by statute or regulation, most commonly including cancer, HIV/AIDS, epilepsy, PTSD, chronic pain, and multiple sclerosis. Physicians must certify that patients have qualifying conditions and would benefit from cannabis, though federal law prohibits physicians from prescribing Schedule I substances, leading to the "recommendation" framework. Patient registration systems issue identification cards that provide affirmative defense against state prosecution. Possession limits typically range from 2-10 ounces of usable cannabis, with some states allowing home cultivation of 6-12 plants. Dispensary licensing involves application processes, background checks, financial disclosures, and operational requirements including security, inventory tracking, and product testing. Mandatory testing protocols vary by state but increasingly include potency analysis for THC and CBD content, screening for pesticides, heavy metals, microbial contaminants, and residual solvents. States like Massachusetts and California maintain among the strictest testing requirements, while others conduct limited or no mandatory testing. Employment protections remain limited. Most states do not require employers to accommodate medical marijuana use, and federal employees and contractors face termination for positive drug tests regardless of state medical authorization. Several state courts have ruled that employers may terminate medical cannabis patients, as in Coats v. Dish Network (Colo. 2015), though some states like Nevada and New Jersey have enacted employment protections.

State-by-State Program Variations

Medical marijuana programs differ dramatically across states in qualifying conditions, possession limits, home cultivation rights, and dispensary access, creating vastly different patient experiences.

California

California's program allows physicians to recommend cannabis for any condition they believe would benefit from treatment. Patients may possess up to 8 ounces of dried cannabis and cultivate up to 6 mature or 12 immature plants, with local jurisdictions permitted to set higher limits. The state operates over 1,000 licensed dispensaries under the Department of Cannabis Control's unified regulatory framework covering both medical and adult-use markets. Medical patients receive tax benefits, paying lower rates than adult-use consumers.

Florida

Florida's program, established by constitutional amendment in 2016, requires physicians to complete state-approved training before recommending cannabis. Qualifying conditions include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis, plus terminal conditions and chronic nonmalignant pain. The state prohibits smokable flower (though this ban was overturned in 2019) and home cultivation. Florida has approximately 900,000 registered patients and over 600 dispensaries, making it the nation's second-largest medical market by patient count.

Oklahoma

Oklahoma's program stands out for its permissive approach, allowing physicians to recommend cannabis for any condition they determine would benefit from treatment. The state has no specific qualifying condition list. Patients may possess up to 3 ounces on their person, 8 ounces at home, and cultivate 6 mature and 6 seedling plants. Oklahoma issued over 2,000 dispensary licenses by 2021, creating intense competition and low wholesale prices that challenged operator profitability.

Pennsylvania

Pennsylvania's Medical Marijuana Program launched in 2018 with 17 qualifying conditions including cancer, epilepsy, inflammatory bowel disease, and opioid use disorder. The state prohibits home cultivation and smoking of cannabis, requiring patients to use vaporization, tinctures, topicals, or other non-combustible forms. Pennsylvania operates approximately 200 dispensaries across the state, with vertical integration requirements ensuring cultivators and processors maintain supply chain control.

New York

New York's program initially launched in 2016 as one of the nation's most restrictive, with limited qualifying conditions and only 10 licensed organizations permitted to operate. The 2021 Marijuana Regulation and Taxation Act dramatically expanded the program while establishing adult-use legalization. Medical patients may possess up to a 60-day supply as determined by their practitioner and may now cultivate plants at home. The state has expanded qualifying conditions to include chronic pain, making the program more accessible.

Texas

Texas operates the Compassionate Use Program, among the nation's most restrictive medical cannabis programs. The program initially covered only intractable epilepsy but expanded in 2021 to include cancer, PTSD, and other conditions. Products are limited to low-THC cannabis containing no more than 1% THC by weight, effectively restricting patients to CBD-dominant products. The state has fewer than 20 licensed dispensaries and prohibits home cultivation.

Mississippi

Mississippi's program began operations in late 2022 after legislative action following the court-invalidated ballot initiative. Qualifying conditions include cancer, Parkinson's disease, Huntington's disease, muscular dystrophy, glaucoma, HIV/AIDS, hepatitis, ALS, Crohn's disease, ulcerative colitis, sickle cell anemia, Alzheimer's disease, PTSD, pain refractory to appropriate opioid management, and severe muscle spasms. Patients may possess up to 3.5 ounces per month purchased from licensed dispensaries, with no home cultivation permitted.

Montana

Montana voters approved medical marijuana in 2004, with the program experiencing significant restrictions in 2011 before expansion resumed. The state's 2020 adult-use legalization ballot measure also reformed the medical program. Qualifying conditions include cancer, glaucoma, HIV/AIDS, cachexia, severe pain, seizures, persistent muscle spasms, and PTSD. Patients may possess up to 1 ounce and cultivate up to 4 mature and 4 seedling plants if they live more than 25 miles from a dispensary.

Market and Business Implications

Medical marijuana programs generate approximately $12 billion in annual sales across 38 states, with distinct market dynamics including vertical integration requirements, limited banking access, and punitive federal tax treatment under Internal Revenue Code Section 280E. Medical-only markets represent both opportunities and challenges for cannabis operators. States like Mississippi, West Virginia, and Alabama offer first-mover advantages for companies establishing operations before potential adult-use expansion. Medical markets typically feature higher per-patient spending than adult-use markets, with patients purchasing more frequently and in larger quantities for therapeutic needs. Wholesale pricing varies dramatically by state supply-demand dynamics. Oklahoma's oversupply drove wholesale flower prices below $1,000 per pound by 2021, while limited-license states like Pennsylvania maintained wholesale prices above $3,000 per pound. Florida's competitive but controlled market sees wholesale prices around $1,800-2,400 per pound depending on quality and testing results. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, though cost of goods sold remains deductible. This creates effective federal tax rates of 60-75% for cannabis operators, significantly impacting profitability. Medical dispensaries can deduct costs directly tied to product acquisition and cultivation but not rent, marketing, administrative salaries, or other standard business expenses. Banking access remains constrained despite FinCEN guidance issued in 2014 outlining how financial institutions can serve cannabis businesses under Bank Secrecy Act compliance frameworks. Most cannabis operators rely on credit unions, regional banks, or cannabis-specific financial service providers, paying premium fees for basic banking services. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House multiple times but not the Senate as of May 2026. Capital markets present additional challenges. U.S. cannabis operators cannot list on the New York Stock Exchange or NASDAQ due to federal prohibition, instead trading on the Canadian Securities Exchange or over-the-counter markets with limited liquidity. This restricts access to institutional capital and creates higher costs of capital compared to other industries. Multi-state operators pursue geographic diversification strategies, though state-by-state licensing and prohibition on interstate commerce require establishing separate operations in each market. Vertical integration requirements in states like Pennsylvania, Florida, and New York force operators to control cultivation, processing, and retail rather than specializing, creating capital inefficiencies but also margin protection. Ancillary businesses including testing laboratories, compliance software providers, security services, and specialized legal and accounting firms serve the medical cannabis industry without touching the plant, avoiding direct 280E implications. Companies like Metrc provide seed-to-sale tracking systems mandated by state regulators, while Confident Cannabis and other platforms facilitate wholesale transactions.

What Medical Professionals and Policy Experts Say

Medical associations, researchers, and policy analysts offer varied perspectives on state medical marijuana programs, generally supporting increased research access while expressing concerns about program implementation and federal-state conflicts. The American Medical Association maintains that cannabis should be rescheduled to facilitate research, stating in policy documents that Schedule I classification creates unnecessary barriers to studying potential therapeutic applications. The organization has not endorsed broad medical marijuana legalization but supports physicians' ability to discuss cannabis with patients and opposes criminal penalties for medical use. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has emphasized in congressional testimony and published research that while cannabis shows promise for certain conditions, the lack of rigorous clinical trials leaves significant questions about optimal dosing, delivery methods, and long-term effects. She has advocated for rescheduling to enable proper FDA-approved drug development. The National Academies of Sciences, Engineering, and Medicine conducted a comprehensive evidence review published in 2017, finding conclusive or substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults, chemotherapy-induced nausea and vomiting, and patient-reported multiple sclerosis spasticity symptoms. The report found moderate evidence for improving sleep outcomes in individuals with sleep disturbance associated with obstructive sleep apnea, fibromyalgia, chronic pain, and multiple sclerosis. According to research published in JAMA Internal Medicine, states with medical cannabis programs experienced 24.8% lower mean annual opioid overdose mortality rates compared to states without such programs, though subsequent research has produced mixed findings on this association. The relationship between medical cannabis access and opioid use remains an active area of investigation. Kevin Sabet, president of Smart Approaches to Marijuana, has argued in public statements and writings that many state medical marijuana programs function as de facto legalization with minimal medical oversight, citing programs like Oklahoma's that lack specific qualifying conditions. He advocates for FDA-approved cannabis medications rather than state-based dispensary systems. The Drug Policy Alliance, which supported many state medical marijuana initiatives, maintains that programs should prioritize patient access, affordability, and protection from discrimination while states work toward broader legalization. The organization has advocated for home cultivation rights, employment protections, and expungement of prior cannabis convictions. State medical marijuana program administrators, speaking at industry conferences and in regulatory proceedings, consistently emphasize the challenges of operating state-legal programs under federal prohibition, particularly regarding banking access, research limitations, and conflicts with federal employment law.

What's Next for Medical Marijuana Programs

Medical marijuana programs face potential transformation through federal rescheduling, continued state-level expansion, and possible congressional action on banking and taxation issues. The DEA's ongoing rescheduling review represents the most significant near-term development. Following HHS's August 2023 recommendation to reschedule cannabis to Schedule III, the DEA published a Notice of Proposed Rulemaking in May 2024. The agency must conduct a formal rulemaking process including public comment and potentially administrative law judge hearings before finalizing any scheduling change. Rescheduling to Schedule III would not legalize cannabis under federal law but would eliminate 280E tax treatment, allowing standard business deductions and dramatically improving operator profitability. Schedule III substances require FDA approval for medical use, creating questions about how existing state programs would interact with federal pharmaceutical regulation. Several states may launch new medical programs in 2026-2027. The Republican state senator's announced intention to draft medical marijuana legislation, reported in May 2026, suggests continued expansion though the specific state remains unidentified in initial coverage. Historically conservative states including Idaho, Nebraska, and Kansas face ongoing advocacy efforts for medical programs. Congressional action on cannabis banking remains possible, with the SAFE Banking Act or comprehensive reform legislation potentially advancing. The 119th Congress convening in January 2025 included members from both parties supporting cannabis reform, though the specific legislative path remains uncertain. State program reforms continue incrementally. Several medical-only states face pressure to add qualifying conditions, particularly chronic pain and PTSD. Home cultivation rights remain contentious, with patient advocates arguing for cultivation access while some regulators and operators oppose it. The transition from medical-only to adult-use markets affects program dynamics. States including New York, New Jersey, and Connecticut launched adult-use sales in 2022-2024 while maintaining separate medical programs with tax advantages and higher possession limits. Medical patient counts typically decline after adult-use implementation, though dedicated medical programs continue serving patients seeking higher potency products and tax savings. Research expansion depends partly on federal scheduling decisions and DEA licensing of additional cultivation facilities for research purposes. The agency approved additional growers beyond the University of Mississippi in 2021, potentially enabling higher-quality research on cannabis's therapeutic effects and risks.

Further Reading and Primary Sources

• Drug Enforcement Administration Notice of Proposed Rulemaking on Cannabis Rescheduling: https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• National Academies of Sciences, Engineering, and Medicine: "The Health Effects of Cannabis and Cannabinoids" (2017): https://nap.nationalacademies.org/catalog/24625
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.deadiversion.usdoj.gov/21cfr/21usc/
• Department of Health and Human Services Recommendation to DEA on Cannabis Scheduling (August 2023): https://www.hhs.gov/about/news/2023/08/29/hhs-recommends-rescheduling-marijuana.html
• Gonzales v. Raich, 545 U.S. 1 (2005): https://supreme.justia.com/cases/federal/us/545/1/
• State Medical Marijuana Laws, National Conference of State Legislatures: https://www.ncsl.org/health/state-medical-cannabis-laws
• Americans for Safe Access State-by-State Medical Marijuana Program Grades: https://www.safeaccessnow.org/state_by_state_medical_marijuana_program_grades
• FDA Approved Cannabis-Derived Medications: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• FinCEN Guidance on Marijuana-Related Businesses (2014): https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses